Kanavig

Moxifloxacin Hydrochloride, the active ingredient in Kanavig, is a fluoroquinolone presented as an ophthalmic solution for ocular use. It treats bacterial eye infections such as conjunctivitis and keratitis in patients who require topical antibiotic therapy, offering broad‑spectrum coverage against Gram‑positive and Gram‑negative organisms.

GNH USA supplies Kanavig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards. The product conforms to EU quality specifications and is manufactured under GMP conditions.

Kanavig (moxifloxacin hydrochloride) is indicated for bacterial infections of the eye, targeting the ocular surface and corneal tissues. - Bacterial conjunctivitis: reduces bacterial load and accelerates resolution of redness, discharge, and irritation. - Bacterial keratitis: eradicates causative organisms to promote corneal healing and preserve visual acuity. - Other ocular bacterial infections: treats infections such as blepharitis or postoperative bacterial inflammation by providing broad‑spectrum antibacterial activity.

Topical ocular administration of Kanavig may be associated with local and systemic adverse reactions, most of which are mild and transient.

Common Side Effects: - Stinging or burning sensation upon instillation. - Temporary blurred vision. - Redness of the conjunctiva. - Mild eye irritation or itching.

Serious or Rare Side Effects: - Allergic contact dermatitis with swelling and erythema. - Corneal ulceration or perforation. - Severe visual loss or sudden decrease in visual acuity.

Before prescribing Kanavig, clinicians should consider several precautionary measures to ensure safe and effective use. - Hypersensitivity assessment: verify no known allergy to fluoroquinolones or any component of the eye drop. - Contact lens use: advise patients to remove lenses before instillation and avoid wearing them until the medication is cleared. - Concomitant ocular steroids: use with caution as steroids may mask signs of infection. - Systemic fluoroquinolone therapy: evaluate risk of additive systemic exposure. - Pregnancy and lactation: consider limited safety data and weigh benefits against potential risks. - Store at room temperature: keep the bottle in its original packaging, protect from light and moisture, and discard after the indicated period after opening.

Kanavig can interact with other ophthalmic or systemic agents, influencing efficacy or safety.

Major Interactions (Avoid): - Concurrent systemic fluoroquinolone therapy: may increase risk of systemic fluoroquinolone‑related adverse events. - Use with topical corticosteroids: can suppress inflammatory response and conceal progression of infection.

Moderate Interactions (Monitor Closely): - Co‑administration with other topical antibiotics: potential antagonism or reduced efficacy. - Combination with non‑steroidal anti‑inflammatory eye drops: may heighten ocular irritation. - Preservative‑containing contact lens solutions: increased risk of corneal toxicity when used shortly after instillation.